⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for NOAC9 - Circulating Tumor DNA Guided Follow-Up in Anal Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: NOAC9 - Circulating Tumor DNA Guided Follow-Up in Anal Cancer

Official Title: NOAC9 - A Phase II Randomised Nordic Anal Cancer Group Study on Circulating Tumor DNA Guided Follow-Up

Study ID: NCT05572801

Conditions

Anal Cancer

Study Description

Brief Summary: This study investigates if circulating tumor DNA can improve the detection of early treatment failure or recurrence in localized squamous cell carcinoma of the anus (SCCA) after curative chemoradiotherapy thereby increasing the potential for cure. This will be done by comparing the standard follow-up program with ctDNA guided imaging follow-up. Secondly, the aim is to establish early interventions against late morbidities.

Detailed Description: Squamous cell carcinoma of the anus (SCCA) is a rare disease with less than 200 new cases in Denmark and Sweden each year and approximately 100 new cases in Norway and Finland but with increasing incidence. Primary treatment is chemo-radiotherapy (CRT) comprising high dose IMRT based radiation therapy with combination chemotherapy of 5-FU and Cisplatin. Overall treatment response is good in small tumors, but less pronounced for high-risk tumors. In absence of complete pathological response after CRT or local recurrence, patients are evaluated for. salvage surgery. The importance of R0 resection on overall survival has been described in several studies. It is suggested that early detection of treatment failure and recurrences increases the chance of possible curative surgery (R0-resection) and thereby overall survival. A follow-up program has 3 purposes 1. To detect lack of complete response to primary treatment 2. Early detection of local or distant recurrences 3. Describing and managing late morbidity Purpose: The main purpose of this follow-up study is to investigate if circulating tumor tDNA can improve detection of early treatment failure or recurrences thereby assisting in increasing the potential for cure. Secondly, to provide evidence for use of imaging and third objective is to establish early intervention against late morbidities.

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: ALL

Healthy Volunteers: No

Locations

Department of Oncology Herlev and Gentofte Hospital, Herlev, Capital Region Of Denmark, Denmark

Department of Oncology, Vejle Hospital, Vejle, The Regions Of Southern Denmark, Denmark

Aarhus University Hospital, Aarhus, , Denmark

Tampere University Hospital, Tampere, , Finland

Turku University Hospital, Turku, , Finland

Haukeland University Hospital, Bergen, , Norway

Oslo University Hospital, Oslo, , Norway

University Hospital of North Norway, Tromsø, , Norway

St. Olav's University Hospital, Trondheim, , Norway

Sahlgrenska University Hospital, Göteborg, , Sweden

Skåne University Hospital Lund, Lund, , Sweden

Karonlinska University Hospital, Stockholm, , Sweden

Norrlands University Hospital, Umeå, , Sweden

Contact Details

Name: Karen-Lise G Spindler, Professor

Affiliation: Department of Experimental Clinical Oncology Aarhus Univeristy Hospital

Role: PRINCIPAL_INVESTIGATOR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: